Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 8/20 | 0.35 |
| ▸ | DRD3 | P35462 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9274343 | 0.80 | SSTR4 (0.36) | HTR3ACHRNA7HTR2A | |
| SCHEMBL1545681 | 0.76 | MAPK14 (0.47) | HTR2ADRD3HTR7 | |
| Hydrochloric Acid SCHEMBL607480 | 0.75 | MAPK14 (0.46) | HTR2ADRD3HTR7 | |
| SCHEMBL23175351 | 0.73 | HTR2A (0.50) | HTR3ACHRNA7HTR2ADRD3HTR7 | |
| SCHEMBL8559886 | 0.69 | HTR2A (0.47) | HTR2ADRD3HTR7 | |
| SCHEMBL9591713 | 0.69 | HTR2C (0.33) | HTR3AHTR2A | |
| SCHEMBL1638955 | 0.67 | HTR2C (0.44) | HTR3AHTR2A | |
| SCHEMBL16165 | 0.67 | HTR2C (0.45) | HTR3AHTR2A | |
| SCHEMBL7997129 | 0.67 | HTR2A (0.36) | HTR3AHTR2A | |
| SCHEMBL9591706 | 0.67 | MAOB (0.46) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653069-B2 | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia | JIANGSU HENGYI PHARMACEUTICAL CO., LTD. (CN) | 2014-02-18 | — | — | US | disclosed |
| US-20110160199-A1 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia | JIANGSU GOWORTH INVESTMENT CO. LTD. (CN) | 2011-06-30 | — | — | US | disclosed |
| EP-2322520-A1 | ARALKYL SUBSTITUTED PIPERIDINE OR PIPERAZINE DERIVATIVES AND THEIR USE FOR TREATING SCHIZOPHRENIA | Jiangsu Guohua Investment Co., Ltd (CN) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160199-A1 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia | REN, GRIK5, CAT | HTR3A 1243/4885CHRNA7 681/4885HTR2A 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.